PhRMA picks a political heavyweight to navigate a stormy drug pricing landscape

The Pharmaceutical Research and Manufacturers of America (PhRMA) has named former U.S. House Majority Leader Eric Cantor as its next president and CEO, effective November 9. Cantor, 63, a Virginia Republican who served in Congress from 2000 to 2014 and later became a Wall Street investment banker at Moelis & Company, takes the helm of one of Washington's most powerful lobbying groups at a particularly turbulent moment for the pharmaceutical industry.

Cantor succeeds Steve Ubl, who led PhRMA for 11 years and will stay on as a strategic adviser through mid-January. The appointment comes as drugmakers face bipartisan scrutiny over pricing — from Trump-era most-favored-nation pricing proposals to the Biden-era Inflation Reduction Act, which allowed Medicare to negotiate drug prices for the first time.

Key Takeaways:

• Cantor will need to navigate potential Democratic oversight of pharma's confidential pricing deals with the White House if Democrats retake the House in November's midterms
• He must also address efforts to regulate U.S. investment in Chinese biotech and the use of AI in life sciences
• During his congressional tenure, Cantor backed Medicare Part D, pediatric disease research funding, and the 21st Century Cures Act

Why it matters: With overwhelming majorities of Americans calling drug prices unreasonable, PhRMA's choice of a seasoned political operator signals the industry is bracing for a high-stakes policy battle — and wants someone who knows Capitol Hill from the inside.